Cerenis Appoints John F. Paolini as Chief Medical Officer
Complete the form below to unlock access to ALL audio articles.
Cerenis Therapeutics has announced the appointment of John F. Paolini, MD, PhD, FACC as Chief Medical Officer.
Dr Paolini will be responsible for the strategic planning and execution of the clinical trials for Cerenis’ portfolio of novel cardiovascular therapies and, most importantly, Cerenis’ lead product,CER-001, a pre-beta HDL mimetic currently in Phase II clinical trials for patients with acute coronary syndrome.
Dr. Paolini has more than 15 years of clinical and research experience in cardiovascular disease, the last decade being focused on clinical development in the pharmaceutical industry: notably, at Merck & Co., Inc he led development programs of novel therapies for dislipidemic patients (Tredaptive® the Nicotinic acid/laropripant combination and Vytorin®/Inegy® the Ezetimibe/Simvastatin combination tablet), and at Bayer Healthcare Pharmaceuticals, he led the clinical development program for a novel anticoagulant agent for patients with atrial fibrillation (Xarelto,® the direct factor Xa inhibitor, rivaroxaban).
He is board certified in Cardiovascular Disease, a Fellow of the American College of Cardiology and has served as a Clinical Associate in Cardiovascular Medicine at the Hospital of the University of Pennsylvania.
Dr. Paolini has been involved in the publication of over fifty abstracts and scientific papers.
Dr. Paolini said, "I am impressed by the progress of the portfolio developed by Cerenis and the scientific excellence of its teams. Cerenis is a leader in the discovery of novel HDL therapies, a new approach to the treatment of cardiovascular disease, which is a primary cause of death and disability worldwide. I am delighted to have the opportunity to contribute my passion for cardiovascular research and my experience in clinical development to the future success of Cerenis. Our goal is to bring these potential ground-breaking new therapies to patients."
"The appointment of Dr. Paolini comes at a crucial time in our development, with our lead drug candidate, CER-001 in Phase II; this product addresses a significant unmet medical need and represents a multibillion dollar opportunity,” said Jean-Louis Dasseux, CEO of Cerenis.
“Dr. Paolini has had an exceptional career in the pharmaceutical industry, having held senior positions at companies such as Merck & Co and Bayer Healthcare Pharmaceuticals. His role will be to drive the clinical development of our HDL programmes and we are confident that his expertise in the field of cardiovascular disease will enable us to achieve our regulatory milestones."
